# US 2014/0194528 A1 · Usage of sodium houttuyfonate on inhibiting idiopathic pulmonary fibrosis and bleomycin induced pulmonary fibrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0194528 A1
- Document ID: US20140194528A1
- Status: Published application
- Kind: A1
- Application number: 14/149,823
- Filed: 2014-01-08
- Published: 2014-07-10
- Earliest claimed: 2013-01-10
- Assignees: Hong Kong Baptist University
- Applicants: Hong Kong Baptist University
- Inventors: Hongxi XU; Yunhui SHEN; Yuanzhi LAO; Kaixian CHEN; Dajian YANG; Shilin CHEN; Zhaoxiang BIAN; Aiping LU; Albert Sun Chi CHAN; Chengyuan LIN
- Web page: https://patentgrep.com/patent/US20140194528A1

## CPC

- A61K 31/121: acyclic
- A61K 31/497: containing further heterocyclic rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a synthetic compound and its therapeutic uses. More particularly, it relates to a compound, Sodium Houttuyfonate, that is an addition compound of sodium bisulfite and houttuynin, and its biological activity of inhibiting idiopathic pulmonary fibrosis and bleomycin induced pulmonary fibrosis

## Claims

### Claim 1

A method for treating or preventing pulmonary fibrosis in a subject in need thereof comprising administering to a subject a composition comprising at least one derivative compound from sodium bisulfite and houttuynin or the chemical equivalent thereof.

### Claim 2 (depends on 2)

The method according to claim 2 wherein said derivative compound comprises sodium houttuyfonate or the chemical equivalent thereof.

### Claim 3 (depends on 1)

The method according to claim 1 wherein said pulmonary fibrosis comprises idiopathic pulmonary fibrosis and bleomycin induced pulmonary fibrosis.

### Claim 4 (depends on 1)

The method according to claim 1 wherein said derivative compound is used in preventing or attenuating pulmonary toxicity in said subject with bleomycin induced pulmonary fibrosis.

### Claim 5 (depends on 1)

The method according to claim 1 wherein said derivative compound is administered orally to said subject.

### Claim 6 (depends on 5)

The method according to claim 5 wherein the oral administration is at a dosage between 45 mg/kg bodily weight and 90 mg/kg bodily weight for at least once a day.

### Claim 7 (depends on 1)

The method according to claim 1 wherein said derivative compound is used in preventing pulmonary toxicity in said subject having been administered or administering with bleomycin as chemotherapeutic agent which causes bleomycin induced pulmonary fibrosis.

### Claim 8

A composition for treating or preventing pulmonary fibrosis in a subject in need thereof comprising at least one derivative compound from sodium bisulfite and houttuynin or the chemical equivalent thereof.

### Claim 9 (depends on 8)

The composition according to claim 8 wherein said derivative compound comprises sodium houttuyfonate or the chemical equivalent thereof.

### Claim 10 (depends on 8)

The composition according to claim 8 wherein said pulmonary fibrosis comprises idiopathic pulmonary fibrosis and bleomycin induced pulmonary fibrosis.

### Claim 11 (depends on 8)

The composition according to claim 8 wherein said derivative compound is used in preventing or attenuating pulmonary toxicity in said subject with bleomycin induced pulmonary fibrosis.

### Claim 12 (depends on 8)

The composition according to claim 8 wherein said derivative compound is administered orally to said subject.

### Claim 13 (depends on 12)

The composition according to claim 12 wherein the oral administration is at a dosage between 45 mg/kg bodily weight and 90 mg/kg bodily weight for at least once a day.

### Claim 14 (depends on 8)

The composition according to claim 8 wherein said derivative compound is used in preventing pulmonary toxicity in said subject having been administered or administering with bleomycin as chemotherapeutic agent which causes bleomycin induced pulmonary fibrosis.